HOOKIPA Appoints Prof. Jean-Charles Soria, Director General of the Gustave Roussy Cancer Center in Paris, to its Board of Dir...
October 19 2020 - 8:00AM
HOOKIPA Pharma Inc. (NASDAQ: HOOK), a company developing a new
class of immunotherapeutics targeting infectious diseases and
cancers based on its proprietary arenavirus platform, today
announced the appointment of Professor Jean-Charles Soria, M.D.,
Ph.D., to its Board of Directors.
“We’re honored to welcome Jean-Charles, a
globally recognized scientist and oncologist, to HOOKIPA’s Board of
Directors,“ said Joern Aldag, HOOKIPA’s Chief Executive Officer.
“Jean-Charles’ is rounding the scientific diversity of our board
with his deep expertise in oncology, immunotherapy, and clinical
development. He will bring enormous value as we are expanding our
clinical pipeline.”
Jean-Charles Soria, M.D., Ph.D., is Professor of
Medicine and Medical Oncology at the University of Paris-Saclay and
currently serves as Director General of the Gustave Roussy Cancer
Center, one of the world's leading cancer research institutes.
During his tenure there, he has held a number of positions,
including Chairman of the Department of Drug Development
(2013-2017), member of the Lung Cancer Division focusing on
targeted therapies (2001-2017) and Director of the Gustave Roussy
SIRIC Research (Site for Integrated Research on Cancer)
Program (2013-2017). From 2017 to 2019, Dr. Soria was Senior Vice
President at AstraZeneca, where he was responsible for early
oncology research and development with specific responsibility for
immunotherapy, antibody-drug conjugates and cell therapy. Dr. Soria
was also Adjunct Professor of Medicine at the MD Anderson Cancer
Center from 2013 to 2017.
Professor Soria is a widely cited clinical
scientist and author or co-author of more than 630 publications in
leading international journals. Dr. Soria is a member of ESMO
(European Society for Medical Oncology), ASCO (American Society of
Clinical Oncology), AACR (American Association for Cancer Research)
and SITC (Society for Immunotherapy of Cancer). He has held various
roles in these organisations. From 2013 to 2017 he was the Editor
in Chief of the ESMO flagship journal Annals of Oncology. Dr. Soria
has received multiple awards from the National Academy of Medecine
(2009) and the National Academy of Sciences (2014) in France. He
received the prestigious ESMO award in 2018.
“HOOKIPA’s arenavirus platform is a versatile
technology designed to target and treat cancer and other diseases
with a potent, tailored immune response,” said Dr. Soria. “Despite
considerable innovation in the field, cancer remains an area of
unmet medical need. I am pleased to join the Company at this
exciting stage as a member of the Board of Directors, and help
advance this innovative technology to make a difference in the life
of people impacted by cancer and other serious diseases.”
About HOOKIPAHOOKIPA Pharma
Inc. (NASDAQ: HOOK) is a clinical stage biopharmaceutical company
developing a new class of immunotherapeutics targeting infectious
diseases and cancers based on its proprietary arenavirus platform
that reprograms the body’s immune system.
HOOKIPA’s proprietary arenavirus-based
technologies, non-replicating (VaxWave®) and replicating (TheraT®),
induce robust antigen-specific CD8+ T cells and
pathogen-neutralizing antibodies. HOOKIPA’s “off-the-shelf” viral
vectors target antigen presenting cells in vivo to activate the
immune system. Both technologies enable repeat administration to
augment and refresh immune responses. As a monotherapy, our
replicating arenavirus technology has the potential to induce
CD8+ T cell response levels previously not achieved by other
immuno-therapy approaches.
HOOKIPA’s non-replicating prophylactic
Cytomegalovirus (CMV) vaccine candidate is currently in a Phase 2
clinical trial for patients awaiting kidney transplantation. To
expand its infectious disease portfolio, HOOKIPA entered into a
collaboration and licensing agreement with Gilead Sciences, Inc. to
research arenavirus-based functional cures for HIV and chronic
Hepatitis B infections.
In addition, HOOKIPA is building a proprietary
immuno-oncology pipeline by targeting virally mediated cancer
antigens, self-antigens and next-generation antigens. The lead
replicating arenavirus oncology product candidates, HB-201 and
HB-202, are in development for the treatment of Human Papilloma
Virus 16-positive cancers. The Phase 1/2 clinical trial for HB-201
was initiated in December 2019. The HB-202 IND application was
cleared by the FDA in June 2020.
Find out more about HOOKIPA online
at www.hookipapharma.com.
HOOKIPA Forward Looking
Statements
Certain statements set forth in this press
release constitute “forward-looking” statements within the meaning
of the Private Securities Litigation Reform Act of 1995, as
amended. Forward-looking statements can be identified by terms such
as “believes,” “expects,” “plans,” “potential,” “would” or similar
expressions and the negative of those terms. Such forward-looking
statements involve substantial risks and uncertainties that could
cause HOOKIPA’s research and clinical development programs, future
results, performance or achievements to differ significantly from
those expressed or implied by the forward-looking statements. Such
risks and uncertainties include, among others, the uncertainties
inherent in the drug development process, including HOOKIPA’s
programs’ early stage of development, the process of designing and
conducting preclinical and clinical trials, the regulatory approval
processes, the timing of regulatory filings, the challenges
associated with manufacturing drug products, HOOKIPA’s ability to
successfully establish, protect and defend its intellectual
property, risks relating to business interruptions resulting from
the coronavirus (COVID-19) disease outbreak or similar public
health crises, the impact of COVID-19 on the enrollment of patients
and timing of clinical results for HB-101 and other programs, and
other matters that could affect the sufficiency of existing cash to
fund operations and HOOKIPA’s ability to achieve the milestones
under the agreement with Gilead. HOOKIPA undertakes no obligation
to update or revise any forward-looking statements. For a further
description of the risks and uncertainties that could cause actual
results to differ from those expressed in these forward-looking
statements, as well as risks relating to the business of the
company in general, see HOOKIPA’s quarterly report on Form 10-Q for
the quarter ended June 30, 2020 which is available on the Security
and Exchange Commission’s website at www.sec.gov and HOOKIPA’s
website at www.hookipapharma.com.
Investors and others should note that we
announce material financial information to our investors using our
investor relations website (https://ir.hookipapharma.com/), SEC
filings, press releases, public conference calls and webcasts. We
use these channels, as well as social media, to communicate with
our members and the public about our company, our services and
other issues. It is possible that the information we post on social
media could be deemed to be material information. Therefore, we
encourage investors, the media, and others interested in our
company to review the information we post on the U.S. social media
channels listed on our investor relations website.
For further information, please contact:
Media
Nina
Waibel
Senior Director -
Communications
nina.waibel@hookipapharma.com |
|
InvestorsMatt
Beck Executive
Director - Investor Relationsmatthew.beck@hookipapharma.com |
|
|
|
Media enquiriesInstinctif
Partnershookipa@instinctif.com +44 (0)20 7457 2020 |
|
|
|
|
|
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Aug 2024 to Sep 2024
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Sep 2023 to Sep 2024